Genmab — Marts 2024

Klarussen

Fint, fint

MadsSkjern

Regeneron har problemer i CD20XCD3.

MadsSkjern

Just a moment...

(firstwordpharma.com)

E_L

Abstract 509: The MPS1/TTK inhibitor, NMS-01940153, synergizes with tisotumab vedotin in colorectal cancer https://aacrjournals.org/cancerres/article/84/6_Supplement/509/737622/Abstract-509-The-MPS1-TTK-inhibitor-NMS-01940153?searchresult=1

lahn1

Det er vist så meget sagt. Lyder til at være en fodfejl hos Regeneron, som der blive rette op. Men sjældent man ser en Priority Review få CRL, tænker jeg.

MarsFars

Ser ud til at der er nogen der sælger på det stærke købssignal fra i går Så deeeet

E_L

Abstract 5071: Minimal residual disease (MRD) status by peripheral blood mononuclear cells (PBMCs) and circulating tumor DNA (ctDNA) demonstrates rapid, deep, and sustained response in patients (Pts) with relapsed/refractory follicular lymphoma (R/R FL) treated with subcutaneous (SC) epcoritamab monotherapy in the pivotal phase 1/2 EPCORE NHL-1 trial https://aacrjournals.org/cancerres/article/84/6_Supplement/5071/736959/Abstract-5071-Minimal-residual-disease-MRD-status?searchresult=1

lahn1

Tak EL !

SEACOP

Supersupport, 12 mdr., med stor tak. Ingen bog, som er god, alt til det gode formål. (link)

SEACOP

Just a moment...

(www.proinvestor.com)

E_L

UBS analyst Xian Deng Reiterates Buy Rating on Genmab A/S (PT 2800) https://www.streetinsider.com/Intl+Ratings/UBS+Reiterates+Buy+Rating+on+Genmab+AS+(GEN%3ADC)+(GMAB)/22976308.html

E_L

and i think Sachin Jain from
Bank of America Securities
Reiterated Buy Yesterday (PT Kr.255.33 mistaken again, must probably be Kr 2553.3)

ProinvestorNEWS

Aktier/middag: Mærsk til bunds efter broulykke i USA - Genmab og Danske topper https://www.proinvestor.com/investornyt/1136612/aktier-middag-maersk-til-bunds-efter-broulykke-i-usa-genmab-og-danske-topper

gentogen

Lidt speciel kommentar fra foregående link: Genmab ligger øverst på grund af lidt nyt fra USA, hvor FDA's rådgivende komite skal mødes. Vi ved ikke, om det handler om Genmab og selskabets nye produkt, det har på vej, Hexabody CD38, men det er der bare meget, der tyder på, at det gør, siger Lars Hytting.

Bulder

Ja, det måtte Hytting da gerne uddybe lidt, hvad det er der tyder på at fda skal snakke om hex38.

E_L

-Use of Minimal Residual Disease as an Endpoint in Multiple Myeloma Clinical Trials

https://www.federalregister.gov/documents/2024/03/26/2024-06314/oncologic-drugs-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request-for

E_L

i don't see Genmab mentioned anywhere, but that is offcourse what they would want to get a potential speedy approval for hexabody-cd38

Bulder

Yes Frontrunner prg together with MRD- neg could speed up the process.

Sukkeralf

But again strange that Hytting immediately thinks Genmab and HexCD38.....orthers could use them same. But nice if Genmab push FDA for that cause then they still cheer for this mighty trigger

Sukkeralf

Do the current phase 1/2 trial have enough patients to get approval in some later line if data looks good?